Literature DB >> 16091242

Therapeutic HIV vaccines: an update.

Yves Lévy1.   

Abstract

The goal of therapeutic immunization in HIV infection is to induce strong and sustained immune responses against HIV. Several arguments suggest that the immune system may contain HIV replication in the long term before declining. The potency on new antiviral regimens in clinic has provided an opportunity to improve the control of the virus replication by the immune system. In clinical terms, this might allow patients to delay or to stop antiviral therapy and to minimize the duration of the exposition to antiviral drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091242     DOI: 10.1007/s11904-996-0002-5

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.495


  37 in total

1.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

3.  Sometimes help may not be enough.

Authors:  Michael M Lederman; Daniel C Douek
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

4.  Therapeutic vaccines for chronic infections.

Authors:  Brigitte Autran; Guislaine Carcelain; Béhazine Combadiere; Patrice Debre
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

5.  Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.

Authors:  Yves Lévy; Hanne Gahéry-Ségard; Christine Durier; Anne-Sophie Lascaux; Cécile Goujard; Vincent Meiffrédy; Christine Rouzioux; Raphaëlle El Habib; Maria Beumont-Mauviel; Jean-Gérard Guillet; Jean-François Delfraissy; Jean-Pierre Aboulker
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

6.  Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.

Authors:  R Tubiana; E Gomard; H Fleury; M L Gougeon; B Mouthon; H Picolet; C Katlama
Journal:  AIDS       Date:  1997-05       Impact factor: 4.177

7.  Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group.

Authors:  E Sandström; B Wahren
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

8.  Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

Authors:  G Carcelain; R Tubiana; A Samri; V Calvez; C Delaugerre; H Agut; C Katlama; B Autran
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study.

Authors:  L E Goh; L Perrin; B Hoen; D Cooper; A Phillips; G Janossy; A Sonnenborg; C Tsoukas; F Lampe; S Kinloch
Journal:  HIV Clin Trials       Date:  2001 Sep-Oct

10.  Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.

Authors:  Gregory K Robbins; Marylyn M Addo; Hien Troung; Almas Rathod; Kathy Habeeb; Benjamin Davis; Howard Heller; Nesli Basgoz; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.